Navigation Links
NeoStem, Inc. Appoints International Expert in Endocrinology and Pharmacology as Vice President of Drug Development and Regulatory Affairs
Date:7/6/2009

inology. Previously he served as Chief Medical Officer at Manhattan Pharmaceuticals, Inc., after serving as Therapeutic Head of the Worldwide Medical Endocrine Care group at Pfizer Inc, New York and, earlier, as Vice President, Global Healthcare Research & Outcomes and Senior Director of Medical & Scientific Affairs at Schering-Plough Corp., NJ, where he was involved in the joint venture with Merck in the clinical development of the novel cholesterol medication, ezetimibe (Zetia). Dr. Harris earned his MD from the Louis Pasteur Faculty of Medicine, University of Strasbourg, France, and his Ph.D. in endocrinology from Erasmus University, Rotterdam, The Netherlands. He was appointed Associate Professor of Medicine at UCLA School of Medicine and Director of the Division of Clinical Pharmacology in the Department of Medicine and Medical Director of the Dept of Technology Development and Transfer and Clinical Trials at Cedars-Sinai Medical Center. Dr. Harris during his tenure at Sandoz (Novartis) Pharma in Switzerland, developed octreotide (Sandostatin(R)) for the treatment of hormone producing tumors of the gut and pituitary. He is currently Adjunct Professor of Pharmacology at NYU Medical School and Visiting Professor of Medicine in the Dept of Endocrinology at Liege University Medical School, Belgium and in the Dept of Clinical Pharmacology at the University Hospital of Lausanne in Switzerland. Dr. Harris is a Fellow of the American College of Physicians, the Royal College of Physicians (UK), the Royal Society of Medicine (UK) and the American College of Clinical Pharmacology. He has served on the editorial boards of several international peer reviewed medical journals and has authored 119 peer reviewed scientific papers in the fields of endocrinology, diabetes mellitus, gastroenterology, oncology, cardiology, allergy, immunology and respiratory medicine. He served on the NIH Center for Scientific Review Special Emphasis Panel for Clinical Cardiovas
'/>"/>
SOURCE NeoStem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NeoStem, Inc. Comments on Recent Selling Pressure
2. Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry
3. Cardinal Health Appoints Bruce Downey to Board of Directors; John McCoy Retires From Board After 22 Years
4. Celleration Appoints Mark T. Wagner President and Chief Executive Officer
5. XLHealth Appoints New Vice President of Contracting and Provider Relations
6. Wisconsin Tobacco Tax Increase Is Positive Step for Health, but Budget Disappoints by Cutting Funding for Tobacco Prevention Programs
7. Verathon Inc. Appoints Kendall Stever as Chief Financial Officer
8. Tyco Electronics Appoints Cuong Do as Senior Vice President, Corporate Strategy & Business Development
9. Symmetry Medical Appoints Chairman and Two Directors
10. GBS/CIDP Foundation International Appoints Patricia A. Bryant as Executive Director
11. DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015 Airy Jeanine is a rising ... music video for her debut song “Mama’s Girl”, launched ... and abstract styling effects, the thematic video for the ... Vimeo, and assorted outlets. It will be integral in ... expanding full-scale marketing strategy. The video promotion campaign spearheaded ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 “ VXi ... of its monthly Tech Report, which features the latest ... a technology expert and special reporter for NewsWatch, conducted ... an advanced noise-cancelling headset, eliminating 90% of ambient noise. ... while texts and emails are important to any professional, ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... a Quaker-based, philanthropic, grant-making foundation committed to raising ... behavioral healthcare is delivered. , The Scattergood Foundation ... advance Behavioral Health Policy and Practice through the ... SoundsLikeIBS Program App is designed to guide ...
(Date:3/26/2015)... Dallas, TX (PRWEB) March 26, 2015 ... of the 32nd annual Dallas Rhinoplasty Symposium and ... the years, reiterated the importance of evidence based medicine ... utilizing evidence from well conducted research. , "We often ... approaches to rhinoplasty, and while we are certainly not ...
(Date:3/26/2015)... San Francisco, CA (PRWEB) March 26, 2015 ... webinars. These will be on the topics of the DAOM ... , The DAOM Program Overview Webinar will be hosted by ... program and provide the next steps on how to prepare ... to 12:30 p.m. March 25, March 27, April 1 and ...
Breaking Medicine News(10 mins):Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:A Device to Tune out Background Noise was Recently Featured on NewsWatch Television 2Health News:SoundsLikeIBS Nominated For 3rd Annual Scattergood Innovation Award 2Health News:Dr. Rod Rohrich Explores Evidence Based Innovations and Safety at the 32nd Annual Dallas Rhinoplasty Symposium 2Health News:ACTCM Announces Upcoming Webinars 2
... Recall covers last two years; lawmakers demand criminal probe ... peanut butter products in 2007 and 2008. , , WEDNESDAY, ... a startling nationwide recall late Wednesday for all peanut ... Georgia plant involved in the current salmonella outbreak. , ...
... be an effective way to reduce urinary incontinence in ... study led by researchers at the University of California, ... Reduce Incontinence by Diet and Exercise (PRIDE) experienced both ... frequency of their incontinence episodes, according to the study. ...
... MENLO PARK, Calif., Jan. 28 The Foundry, ... that it has completed a $5M,Series A financing ... Ventures,and Split Rock Partners, and added two new ... Both of the new partners have extensive experience ...
... control exercises, when performed in conjunction with other forms ... patients with persistent low back pain, according to a ... Physical Therapy ( PTJ ), the scientific ... addition to feeling less pain, patients performing these types ...
... N.J., Jan. 28 CCA Industries, ... announced today that the Board of ... dividend for the 1st Quarter ending ... Shareholders of record February 3, 2009 ...
... (NYSE: PRA ) announced today that ... with its proposed sponsored demutualization of,the PICA Group ... doctors of podiatric medicine. The proposed demutualization is ... a special meeting to be,held on March 31, ...
Cached Medicine News:Health News:All Products at Georgia Peanut Plant Recalled 2Health News:All Products at Georgia Peanut Plant Recalled 3Health News:All Products at Georgia Peanut Plant Recalled 4Health News:Weight loss reduces incontinence in obese women, UCSF study shows 2Health News:The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company 2Health News:The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company 3Health News:The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company 4Health News:Report shows motor control exercises reduce persistent low-back pain 2Health News:ProAssurance Receives Regulatory Approvals for Transactions with the PICA Group and Georgia Lawyers Insurance Company 2
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
(Date:3/26/2015)... and VANCOUVER, British Columbia, March 26, 2015 /PRNewswire/ ... provided a summary of clinical developments and announced ... Clinical Developments and Anticipated Near-term ... OncoGenex and Teva agreed to negotiate the termination ... OncoGenex. Negotiations of the final termination agreement are ...
(Date:3/26/2015)... S.C. , March 26, 2015 ... told by their existing PACS vendor their system ... (CMH) determined that they needed a better structured ... Hospital selected Avreo interWORKS due to its interface ... modern meaningful use standards through to the hospital,s ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
Plastic Citrate Tube, .109M / 3.2%...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... EDTA K2 / gel tubes are ... for molecular diagnostics and for viral ... whole blood remain stable at room ... For optimal results, it is recommended ...
Medicine Products: